alli Report - News about low-dose Xenical (orlistat)

alliReport

Free! Join

alli

Forum

Discussions

Your INDEPENDENT source of news about the new diet drug alli (low-dose Xenical)

Neither affiliated with nor endorsed by GlaxoSmithKline

What Is alli?

What Studies Are Underway?

What Are the Pros & Cons?

	The alli Report - 2006 News Archive
	Indexed below are all of the reports that appeared during 2006 on the new non-prescription version of Xenical (orlistat), which is being marketed as alli. The alli Report, updated daily, provides the latest news and reviews related to alli so those waiting eagerly for an over-the-counter anti-obesity drug approved by the FDA will have the latest information.
	alli News for December 2006 -- News About Half-Strength Xenical
	Why No FDA Action on Diet Pill alli (low-dose Xenical)?
	alli News for November 2006 -- News About Half-Strength Xenical
	Australia Orders TV Ad for O-T-C Xenical Pulled for Breaching Ad Code Survey: Twice as Many U.S. Dieters Use Supplements as Prescription Drugs Diet Drug Acomplia Seen on Slow FDA Track for Approval Decision
	alli News for October 2006 -- News About Half-Strength Xenical
	What's the FDA Holdup on Diet Pill alli (O-T-C Xenical)? More Promising Results Reported for Experimental Diet Drug Qnexa Experimental Diet Drug Contrave Seen Promising in Small Phase III Trial
	alli News for September 2006 -- News About Half-Strength Xenical
	Study: O-T-C Strength Orlistat (alli) Produces Weight Loss, Other Benefits Study: Diet Drug Xenical (Orlistat) Aids Glucose Control in Diabetics Study: Xenical (Orlistat) Helps Obese Teens and Preteens Lose Weight
	alli News for August 2006 -- News About Half-Strength Xenical
	FDA Ban on Diet Pills Containing Ephedra Reinstated by Appeals Court Rimonabant Safety for Obese Individuals With Mild Depression Questioned Sanofi 'Hopeful,' But U.S. Outlook for Diet Drug Acomplia Remains Cloudy
	alli News for July 2006 -- News About Half-Strength Xenical
	How Much Room Does Price of Acomplia Leave for alli (Low-Dose Xenica)? Diet Pill Meridia Helps Very Obese Young Teens Lose Weight in Trial Acomplia May Help Prevent Weight Gain Common to Antidepressants
	alli News for June 2006 -- News About Half-Strength Xenical
	Diet Pill Acomplia on Sale for Just Over $100 per Month in Britain Diet Drug Xenical Under Renewed Attack by Consumer Advocates Pfizer Licenses Promising Diet Drug in Early Trials From Bayer
	alli News for May 2006 -- News About Half-Strength Xenical
	No Early FDA Action on Diet Pill Acomplia Now Seems Likely Wyeth Moves Step Closer to Final Resolution of "Fen-Phen" Claims Promising Early Results Reported for Experimental Diet Drug Qnexa
	alli News for April 2006 -- News About Half-Strength Xenical
	Glaxo Launches Weight-Loss Website Prior to FDA Action on alli FDA Finds Low-Dose Xenical (alli) "Approvable" for Over-the-Counter Sale Sanofi Hints It Also Seeks Approval of Acomplia for 'Metabolic Disorders'
	alli News for March 2006 -- News About Half-Strength Xenical
	Harvard Researchers Say FDA Approval of alli (O-T-C Orlistat) Is Uncertain European Commission Warns Fake Acomplia Is Being Sold on Internet Hopes for Early FDA Action on Acomplia Dim as FDA Panel Scrubs Meeting
	alli News for February 2006 -- News About Half-Strength Xenical
	Old Acomplia Study Creates New Excitement When Reported in JAMA Indian Pharma Reports Early Progress on Drug That Works Like Acomplia Sanofi: Acomplia Could Be on Market by June 30th With Feb. OK from FDA New Acomplia Trial Announced, But Enrollment Said Amost Completed
	alli News for January 2006 -- News About Half-Strength Xenical
	Sanofi Expresses Confidence Acomplia Will Be on the U.S. Market Soon Researchers See Expected FDA Approval of alli as Good News for Dieters FDA Advisory Panels Back Over-the-Counter Sale of Low-Dose Xenical FDA Raises Warning Flags on Over-the-Counter Sale of Low-Dose Xenical Article Calls on FDA to Limit Acomplia to Those "Who Need It to Survive" Report: Acomplia Could Be Approved by FDA 'As Early as Next Month' Report: Acomplia Still Must Overcome "Skepticism About Its Side Effects"

Other Diet Resources

Privacy Policy | Terms and Disclaimers | About the alli Report

Contact Us

We subscribe to the HONcode principles of the HON Foundation.

This is an independent news site reporting on alli, a half-strength version of the diet drug Xenical (orlistat), which GlaxoSmithKlein hopes to market under the trademarked name alli. Nothing on this site is intended to infringe on that trademark. Nothing on this site is intended as medical advice. The information provided is for informational purposes only. Always consult a doctor or medical professional with questions regarding a medical condition.